AI assistant
ATAI Life Sciences N.V. — Director's Dealing 2021
Aug 25, 2021
32049_dirs_2021-08-25_984fabe8-17ab-495d-a8e7-78c88662ef95.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3/A — Form 3/A
Issuer: ATAI Life Sciences N.V. (ATAI)
CIK: 0001840904
Period of Report: 2021-06-17
Reporting Person: Angermayer Christian (Director, 10% Owner)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Shares | 27805200 | Indirect |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Convertible Notes | $ | Common Shares (2367200) | Indirect |
Footnotes
F1: The reporting person's original Form 3 and subsequently filed Form 4 inadvertently understated this amount by 8,320,000 shares.
F2: Apeiron Investment Group Ltd. is the co-managing member of Presight Capital Management I, LLC, which is the general partner of Presight II, L.P. Therefore, Apeiron Investment Group Ltd. may be deemed to share beneficial ownership of the Common Shares held by Presight II, L.P. Apeiron Investment Group Ltd. is owned and controlled by Christian Angermayer. Mr. Angermayer may be deemed to have beneficial ownership over the shares held by Apeiron Investment Group Ltd. and Presight II, L.P.
F3: The Convertible Notes are currently exercisable and will mature on September 30, 2025.
F4: The reporting person's original Form 3 inadvertently overstated this amount by 5,952,800 shares.
F5: The conversion price for the Convertible Notes is Euro 17.00 per share.